The Horizon 21 programme currently brings together 11 teams from different european research sites, led by clinical researchers.
The programme develops collaborations with other clinicians, inside and outside Europe.
Detecting early changes related to Alzheimer’s disease in adults with Down syndrome can be difficult due to the presence of intellectual disability and other health issues.
The diagnosis of Alzheimer’s disease in persons with Down syndrome requires appropriate evaluation tools and a specialized team with significant experience.
In order to conduct research projects, the investigating centers need to work hand in hand and harmonize their protocols so that data can be compared and combined.
This consortium also collaborates with other research centers all over the world.
–> For a unique european cohort (over 1 000 patients) in order to develop clinical trials.

Trinity Research, Ageing & Intellectual Disabilities
Trinity College
Dublin – Ireland

Division of Alzheimer Neurobiology, and Department of Geriatric Medicine,
Karolinska Institute Hospital Huddinge
Stockholm – Sweden

Department of Forensic and Neuro-developmental Sciences
Institute of Psychiatry Psychology and Neuroscience
Kings College
London – England

Anne-Sophie REBILLAT
Geriatric outpatient clinic, Institut Jérôme Lejeune
Paris – France

Ageing and Health Norwegian National Advisory Unit
Vestfold Hospital Trust
Tønsberg – Norway
Oslo University Hospital – Oslo, Norway

Henrik ZETTERBERG
Institute of Neuroscience and Physiology
Department of Psychiatry and Neurochemistry
University of Gothenburg
Mölndal – Sweden

Department of Neurology,
Ludwig-Maximilians-Universität München
Munich – Deutschland

Alzheimer Down Unit, Department of Neurology,
Hospital de la Santa Creu i Sant Pau
Fundacio Catalana Sindrome de Down
Barcelona – Spain

Disabilities Research Group Department of Psychiatry,
University of Cambridge
Cambridge – England

Dichterbij, Center for Intellectual Disabilities
Gennep – The Netherlands